|1.||Sandell, Johan: 2 articles (05/2013 - 08/2010)|
|2.||Juréus, Anders: 1 article (08/2010)|
|3.||Johnson, Allan E: 1 article (08/2010)|
|4.||Neelissen, Jan A M: 1 article (08/2010)|
|5.||Swahn, Britt-Marie: 1 article (08/2010)|
|6.||Svensson, Samuel P S: 1 article (08/2010)|
|7.||Jeppsson, Fredrik: 1 article (08/2010)|
|8.||Sunnemark, Dan: 1 article (08/2010)|
|9.||Farde, Lars: 1 article (08/2010)|
|10.||Johnström, Peter: 1 article (08/2010)|
08/01/2010 - "Taken together, the preclinical profile of AZD4694 suggests that fluorine-18 labeled AZD4694 may have potential for PET-visualization of cerebral beta-amyloid deposits in the living human brain."
08/01/2010 - "Ex vivo binding data in aged Tg2576 mice after intravenous administration of [(3)H]AZD4694 showed selective binding to beta-amyloid deposits in a reversible manner. "
08/01/2010 - "In cortical sections from human Alzheimer's disease brain [(3)H]AZD4694 selectively labeled beta-amyloid deposits in gray matter, whereas there was a lower level of non-displaceable binding in plaque devoid white matter. "
05/30/2013 - "In support of a metabolite study, the β-amyloid plaque neuroimaging positron-emission tomography radioligand AZD4694 was labeled with carbon-14 in 10 radiosynthetic steps starting from radiolabeled carbon dioxide. "
05/30/2013 - "Carbon-14 radiosynthesis of the benzofuran derivative and β-amyloid plaque neuroimaging positron emission tomography radioligand AZD4694."
|2.||Alzheimer Disease (Alzheimer's Disease)